OBJECTIVE: To determine the E-cadherin and beta-catenin expression phenotype in untreated primary prostate cancer and corresponding bone metastases. MATERIALS AND METHODS: Paired bone metastasis and primary prostate specimens were obtained from 14 men with untreated metastatic prostate carcinoma. The tumours were histologically graded by an independent pathologist. Expression of mRNA for E-cadherin and beta-catenin was detected within the tumour cells using in-situ hybridization with a 35S-labelled cDNA probe. The expression of E-cadherin and beta-catenin were graded as uniform, heterogeneous or negative. RESULTS: The mRNA for E-cadherin was expressed in 13 of 14 primary carcinomas and 11 bone metastases; beta-catenin was expressed by 13 and nine, respectively. Of the primary tumours, nine expressed E-cadherin and beta-catenin uniformly; in contrast, all metastases had down-regulated E-cadherin and/or beta-catenin. CONCLUSIONS: The down-regulation of E-cadherin and beta-catenin are a feature of the metastatic phenotype, which may be a significant factor in the genesis of bone metastases. However, this does not appear to be reflected in the expression of these molecules in the primary tumours.
OBJECTIVE: To determine the E-cadherin and beta-catenin expression phenotype in untreated primary prostate cancer and corresponding bone metastases. MATERIALS AND METHODS: Paired bone metastasis and primary prostate specimens were obtained from 14 men with untreated metastatic prostate carcinoma. The tumours were histologically graded by an independent pathologist. Expression of mRNA for E-cadherin and beta-catenin was detected within the tumour cells using in-situ hybridization with a 35S-labelled cDNA probe. The expression of E-cadherin and beta-catenin were graded as uniform, heterogeneous or negative. RESULTS: The mRNA for E-cadherin was expressed in 13 of 14 primary carcinomas and 11 bone metastases; beta-catenin was expressed by 13 and nine, respectively. Of the primary tumours, nine expressed E-cadherin and beta-catenin uniformly; in contrast, all metastases had down-regulated E-cadherin and/or beta-catenin. CONCLUSIONS: The down-regulation of E-cadherin and beta-catenin are a feature of the metastatic phenotype, which may be a significant factor in the genesis of bone metastases. However, this does not appear to be reflected in the expression of these molecules in the primary tumours.
Authors: Christopher L Hall; Honglai Zhang; Shobun Baile; Mats Ljungman; Stuart Kuhstoss; Evan T Keller Journal: Cancer Res Date: 2010-11-23 Impact factor: 12.701
Authors: Jeroen T Buijs; Niek V Henriquez; Petra G M van Overveld; Geertje van der Horst; Peter ten Dijke; Gabri van der Pluijm Journal: Clin Exp Metastasis Date: 2007-11-16 Impact factor: 5.150
Authors: Jeroen T Buijs; Cyrill A Rentsch; Geertje van der Horst; Petra G M van Overveld; Antoinette Wetterwald; Ruth Schwaninger; Niek V Henriquez; Peter Ten Dijke; Fran Borovecki; Regula Markwalder; George N Thalmann; Socrates E Papapoulos; Rob C M Pelger; Slobodan Vukicevic; Marco G Cecchini; Clemens W G M Löwik; Gabri van der Pluijm Journal: Am J Pathol Date: 2007-09 Impact factor: 4.307
Authors: Maahum Haider; Xiaotun Zhang; Ilsa Coleman; Nolan Ericson; Lawrence D True; Hung-Ming Lam; Lisha G Brown; Melanie Ketchanji; Belinda Nghiem; Bryce Lakely; Roger Coleman; Bruce Montgomery; Paul H Lange; Martine Roudier; Celestia S Higano; Jason H Bielas; Peter S Nelson; Robert L Vessella; Colm Morrissey Journal: Clin Exp Metastasis Date: 2015-12-14 Impact factor: 5.150
Authors: Boris Dasen; Tatjana Vlajnic; Chantal Mengus; Christian Ruiz; Lukas Bubendorf; Giulio Spagnoli; Stephen Wyler; Paul Erne; Thérèse J Resink; Maria Philippova Journal: J Pathol Clin Res Date: 2016-11-26